BNCC Hepatitis B Virus Whole Genome DNA Standard

HBV exhibits extremely high genodiversity, with at least nine genotypes (A-I). Genotype D is widely prevalent globally, and strains C and D are more likely to cause chronic infection and rapid disease progression, making them key targets for hepatitis B prevention and research.

Precise research relies heavily on reliable standards. BNCC's newly launched HBV C and D genotype whole-genome DNA standards offer the following advantages:

1. Precise Quantification, Stable and Reliable:

Utilizing digital PCR (ddPCR) technology for rigorous quantification, ensuring precise and controllable concentrations for each batch with minimal batch-to-batch variation. Measurement values ​​are traceable to international standards, providing a solid foundation for reproducibility and cross-platform comparability of experimental results.

2. Safe and Widely Applicable:

Prepared through genetic engineering, the virus's natural infectivity is completely removed, allowing for safe operation in Biosafety Level 1 (BSL-1) laboratories, eliminating the risk of infection for laboratory personnel. Compatible with various PCR platforms and detection methods, overcoming the biosafety limitations of clinical samples.

3. Rigorous Quality Control and Certification

Through multiple rounds of purity testing, integrity verification, and long-term stability testing, the products are ensured to be free of impurities and contamination, with intact genomes and no degradation, meeting the high standards required for scientific research, clinical quality control, and reagent development.

Hepatitis B prevention and control begins with accurate diagnosis and relies on scientific research. BNCC's HBV C and D type whole-genome DNA standards, with their core advantages of full sequence coverage, precision, stability, safety, and compliance, help strengthen the testing quality control system, accelerate vaccine and drug development, and propel hepatitis B prevention and control research to a deeper level.